Clinical Trials Logo

Esophagitis clinical trials

View clinical trials related to Esophagitis.

Filter by:

NCT ID: NCT04821310 Recruiting - Esophagitis Clinical Trials

Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years

Start date: January 13, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the outcomes, tolerability and safety of 2 different doses of oral pantoprazole (full healing dose, half healing dose), assigned based upon weight, for the maintenance of healing of erosive esophagitis in pediatric participants aged 1 to 17 years with endoscopically-confirmed, healed erosive esophagitis.

NCT ID: NCT04671446 Recruiting - Clinical trials for Eosinophilic Esophagitis

Identification of Autoantigens in EGPA and Severe Eosinophilic Asthma

IDEA
Start date: December 10, 2020
Phase:
Study type: Observational

In this project the investigators will look for auto-antibodies to relevant proteins both in native form and importantly in post-translationally modified forms. Potential modified auto-antigens are eosinophil proteins (analogous to the cytoplasmic neutrophil proteins identified in vasculitides such as Granulomatosis with Polyangiitis (formerly known as Wegener's granulomatosis) and alternatively structural proteins such as collagen V. As well as advancing the understanding of asthma pathology, identifying a serum auto-antibody that could then be used as a clinical blood test, analogous to anti-cyclic citrullinated peptide (CCP) antibodies in rheumatoid arthritis, may revolutionise diagnosis of severe eosinophilic asthma and Eosinophilic Granulomatosis with Polyangiitis (EGPA). There is a considerable burden of undiagnosed severe eosinophilic asthma in part due to difficulties in definitive diagnosis and a diagnostic blood test would help diagnose these patients, allowing them to receive necessary treatment.

NCT ID: NCT04657848 Recruiting - Gastric Cancer Clinical Trials

Preliminary Efficacy Analysis of Cheng's Giraffe Reconstruction After Proximal Gastrectomy

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

In the past years, the adenocarcinoma of the esophagogastric junction (AEG) has been increasing obviously in China. It may be caused by the reason of increased body weight, alcohol consumption, gastroesophageal reflux disease and premalignant. In western countries, the 5-year rate of advanced AEG was less than 30%, it was the same in China. There was significant difference in epidemiology, pathogenic mechanism, biological characteristics and prognosis between AEG and antrum tumors, so AEG was regarded as a kind of independent disease. Up till now, the scope of lymph node dissected, the selection of operation approach, the resection range and the digestive tract reconstruction for the treatment of AEG were in dispute, especially in the reconstruction of digestive tract after operation. The purpose of this study is to investigate the efficacy and safety of the proximal gastrectomy combined with Giraffe anastomosis for early adenocarcinoma of esophagogastric junction.

NCT ID: NCT04653324 Recruiting - Clinical trials for Eosinophilic Esophagitis

A Registry for the Food Allergy Community

FPR
Start date: August 24, 2017
Phase:
Study type: Observational [Patient Registry]

The FARE Patient Registry will serve as a prospective, observational food allergy reporting system that stores detailed health and other basic information about patients' real-world experiences with food allergies, to encourage open sharing of de-identified data and participation in clinical trials. The FARE Patient Registry intends to make and support scientific discoveries by enabling the food allergy community to participate directly in research.

NCT ID: NCT04626609 Recruiting - Clinical trials for Eosinophilic Esophagitis (EoE)

Prostaglandin and Cannabinoid Receptors in EoE

Start date: July 1, 2021
Phase:
Study type: Observational

The purpose of this study is to investigate prostaglandin and cannabinoid receptors and their endogenous ligands in eosinophilic esophagitis (EoE). A prostaglandin D2 receptor antagonist has been shown to improve disease symptoms suggesting a regulatory role for bioactive lipids in EoE. Prostaglandin D2 and E2, and endocannabinoids are lipid mediators that govern the functional and inflammatory behavior of immune cells critical for EoE development. The prostaglandin D2 and E2 receptor axis, and the components of the endocannabinoid may be involved in the pathogenesis of EoE.

NCT ID: NCT04531475 Recruiting - Reflux Esophagitis Clinical Trials

Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis

Start date: January 22, 2019
Phase: Phase 2
Study type: Interventional

The purpose of the study is to investigate the efficacy and dose-effect relationship of X842 capsules at different dosages in the treatment of reflux esophagitis for 4 weeks in comparison with lansoprazole enteric-coated capsules.

NCT ID: NCT04506593 Recruiting - Constipation Clinical Trials

Indiana University Gastrointestinal Motility Diagnosis Registry

Start date: November 2014
Phase:
Study type: Observational [Patient Registry]

Develop a registry (list of patients) with accurate clinical motility diagnosis. This registry will help the doctors to identify the patients with specific disease conditions. It will also help in promoting future research in gastroenterology motility disorders

NCT ID: NCT04416217 Recruiting - Clinical trials for Eosinophilic Esophagitis

Eosinophilic Esophagitis Steroid Safety Study

EESY
Start date: October 7, 2019
Phase:
Study type: Observational

This observational study will follow pediatric patients with eosinophilic esophagitis who are scheduled to begin topical steroid treatment, from the initiation of treatment longitudinally to determine the safety profile of the drug.

NCT ID: NCT04341428 Recruiting - Clinical trials for Healed Erosive Esophagitis

Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Start date: July 2, 2020
Phase: Phase 3
Study type: Interventional

This study aims to demonstrate the noninferiority of DWP14012 to Lansoprazole 15 mg in the maintenance effect of treatment and confirm the safety of DWP14012 in patients with healed erosive esophagitis confirmed on EGD after medication treatment.

NCT ID: NCT04255693 Recruiting - Clinical trials for Gastroesophageal Reflux Disease

Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence

Start date: January 31, 2020
Phase: N/A
Study type: Interventional

This study is aimed to investigate the role of long-term diet adherence on manifestations of gastroesophageal reflux disease